Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

Bal T., çabalak m.

Annals of Medical Research, vol.27, no.8, pp.2067-2071, 2020 (TRDizin)

Abstract

Aim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy ingenotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey.Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mgof SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who hadcompleted the duration of treatment and had known virological response status were evaluated for treatment outcomes.Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups,respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experiencedvirologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common(11.6%) adverse event was ribavirin-related hemolytic anemia.Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile innon-cirrhotic Turkish patients infected with HCV genotype 2 or 3.